Cutting-edge research paves way for cancer treatment.
Scientists have developed 3D mini-organs from human fetal brain tissue that self-organize in vitro. These lab-grown organoids open up a brand-new way of studying how the brain develops.
Electricity could be used to enhance a specific chemical reaction in the synthesis of prospective medicinal drugs.
As the world moves away from gas towards electricity as a greener power source, the to-do list goes beyond cars. The vast global manufacturing network that makes everything from our batteries to our fertilizers needs to flip the switch, too.
A study from UChicago chemists found a way to use electricity to boost a type of chemical reaction often used in synthesizing new candidates for pharmaceutical drugs.
Cutting-edge research engineers skin bacteria to treat acne, presenting a novel therapeutic approach for skin conditions.
In a study led by the Translational Synthetic Biology Laboratory Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University, an international research team has successfully engineered Cutibacterium acnes, a type of skin bacterium, to secrete a therapeutic molecule to treat acne symptoms. This innovative approach holds promise for addressing skin alterations and other diseases using living therapeutics.
Engineering smart skin bacteria
Continue reading “Scientists engineer smart bacteria that live in your skin to treat acne” »
New research from the Institute of Psychiatry, Psychology & Neuroscience has found an association between a reduction in gray matter in the brain and early onset psychosis (EOP).
The study, published in Molecular Psychiatry, is the largest ever brain imaging study in EOP and has provided unprecedented levels of detail about the illness. It shows that in contrast to other mental health disorders, people with EOP have a reduced volume of gray matter across nearly all regions of their brain. Researchers hope that this detailed mapping could be used to assist in future diagnosis, as well as to track the effects of treatment in patients with EOP.
EOP occurs before the age of 18 during a critical period of development in the brain. Individuals diagnosed with the illness are likely to experience severe and long-lasting symptoms that respond less well to treatment. Despite this, research into EOP has been limited in sample size and statistical power.
Textile research has highlighted the advances in electroluminescent threads as suitable biomaterials for driving growth in the wearable electronics market. While the direct embroidery of textiles with custom designs and patterns can offer substantial benefits, machine embroidery can challenge the integrity of these threads.
In a new report of applied science and engineering published in Science Advances, Seungse Cho and a team of scientists in biomedical engineering and medicine in the U.S., present embroiderable, multicolor, electroluminescent threads in blue, green, and yellow, that show compatibility with standard embroidery methods.
The researchers used the threads to stitch decorative designs onto a variety of consumer fabrics, without compromising their wearability or light-emitting capacity. The scientists illuminated specific messages or designs on the consumer products for the purpose of developing emergency alerts on helmet liners and as physical hazard signs.
The Utah-based pharmaceutical company has trained a large language model to enable scientists to tap into dozens of machine learning models at once, saving them time during drug development.
Year 2021 face_with_colon_three
Creatine plays a pivotal role in cellular bioenergetics, acting as a temporal and spatial energy buffer in cells with high and fluctuating energy requirements (1). Jeopardizing delicate creatine homeostasis can be detrimental to many energy-demanding tissues, including the brain. For instance, cerebral creatine hypometabolism accompanies various neurological conditions, including a number of developmental disorders (2, 3), neurodegenerative and cerebrovascular diseases (4, 5), and brain cancer (6). A reduced creatine availability in the brain has been thus recognized as an apposite therapeutic target, and supplying exogenous creatine to compensate for a disease-driven shortfall emerged as a first possible approach. However, early success in animal models of neurological diseases was not corroborated in human trials, with the use of creatine supplementation proved largely disappointing in clinical studies with a number of symptomatic neurological disorders [for a detailed review, see (7)]. A meager delivery of creatine to the brain could be partly due to a low activity/density of creatine transporter (CT1 or SLC6A8), a transmembrane sodium-and chloride-dependent protein that mediates creatine uptake into the target cells (8). For that reason, the upregulation of CT1 function has been identified as an innovative course of action to facilitate creatine uptake, with several exotic agents and routes were cataloged so far, including glucocorticoid-regulated kinases, mammalian target of rapamycin, ammonia, and Klotho protein (9).
Besides other vehicles, Klotho protein (Clotho; HFTC3) is put forward as a possible stimulator of CT1 function that can uplift creatine allocation to the target tissues. This membrane-bound pleiotropic enzyme (also exists in a circulating form) participates in many metabolic pathways, including calcium-phosphate metabolism, nutrient sensing, and remyelination (10). Klotho is highly expressed in neuronal cells of the cerebral cortex, cerebellum, and spinal cord (11). The role of Klotho in high-phosphate energy metabolism modulation was revealed a few years ago when Amilaji et al. (12) found that the co-expression of Klotho protein increases a creatine-induced current in CT1-expressing cells. The authors reported that the current through CT1 was a function of the extracellular creatine levels, with the maximal creatine-induced current was higher in cells expressing CT1 together with Klotho than in cells expressing CT1 alone (29.5 vs. 20.2 nA).
Laboratory “copilots” and automated labs are AI’s latest contribution to speeding up the development of new drugs, chemicals and materials. Why it matters: Scientific discovery itself must speed up if the world is to address its challenges — from climate change to personalized treatments for cancer — fast enough to make a difference. In scientific research, “manual effort is not scalable,” writes Microsoft Health Futures’ Hoifung Poon in the…
The first functional semiconductor made from graphene has been created at the Georgia Institute of Technology. This could enable smaller and faster electronic devices and may have applications for quantum computing.
Credit: Georgia Institute of Technology.
Continue reading “First functional semiconductor made from graphene” »
The therapy—developed at the University of Nebraska Medical Center (UNMC)—relies on both the immune system to fight key aspects of Alzheimer’s, plus modified cells that zero in on the brain protein plaques that are a hallmark of the disease.
In patients with Alzheimer’s, amyloid-beta protein forms plaques that prevent nerve cells from signaling each other. One theory is that this might cause irreversible memory loss and behavior changes characteristic of Alzheimer’s disease.
The new study was recently published in the journal Molecular Neurodegeneration. Researchers used genetically modified immune-controlling cells called Tregs to target amyloid-beta.
